Central Nervous System News and Research

RSS

DiaGenic third quarter income increases from NOK -9.3 million to NOK -9.6 million

DiaGenic: The interim report for the third quarter 2010 was approved by the Board of Directors on 28 October 2010.

29 Oct 2010

Scientists identify potential new treatment for Nipah and Hendra viruses

Scientists at Weill Cornell Medical College have identified a potential new treatment for the Nipah and Hendra viruses, two lethal and emerging viruses for which there is currently no treatment or vaccine available. The approach could also lead to new therapies for measles, mumps and the flu. The new research appears in today's edition of the prestigious journal Public Library of Science (PLoS) Pathogens.

29 Oct 2010

StemCells initiates HuCNS-SC second clinical trial for Batten disease in children

StemCells, Inc. announced today that it has initiated a second clinical trial of its HuCNS-SC product candidate (purified human neural stem cells) in neuronal ceroid lipofuscinosis (NCL, also often referred to as Batten disease), a fatal neurodegenerative disorder in children.

29 Oct 2010

AACN joins call for system-wide programs for medication reconciliation

The American Association of Critical-Care Nurses (AACN) added its bold voice to hospital healthcare leaders by endorsing a white paper that calls for system-wide programs for medication reconciliation — the process of verifying that current patient medications are correct, medically safe and necessary.

28 Oct 2010

MedAvante's centralized ratings to be used in Rexahn's Serdaxin Phase 2a study in MDD patients

MedAvante, Inc., the leader in centralized expert evaluation of central nervous system (CNS) disorders, and Rexahn Pharmaceuticals, Inc. a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, announced that Rexahn will use MedAvante 's Remote Centralized Ratings™ in their randomized, double-blind, placebo-controlled Phase 2b clinical study assessing the efficacy of Serdaxin® in patients with major depressive disorder (MDD).

27 Oct 2010

Salk discovers potential new target for MS

Scientists are closer to solving one of the many mysteries of multiple sclerosis and other demyelinating diseases, thanks to a recent study conducted at the Salk Institute for Biological Studies. The research revealed a previously unknown connection between two ion channels, which, when misaligned, can cause the many bizarre symptoms that characterize the condition.

26 Oct 2010

UCI scientists receive CIRM grants to improve stem cell treatments

UC Irvine scientists will receive grants totaling $9.35 million to help create stem cell treatments for retinitis pigmentosa, Huntington's disease and traumatic brain injury.

25 Oct 2010

Arena's NDA receives Complete Response Letter for lorcaserin

Arena Pharmaceuticals, Inc. and Eisai Inc. announced that the US Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding Arena's New Drug Application (NDA) for lorcaserin. Lorcaserin is intended for weight management, including weight loss and maintenance of weight loss, in patients who are obese

25 Oct 2010

Scientists discover new cell that may limit inflammation in CNS

Scientists at Barrow Neurological Institute have recently made discoveries about a type of cell that may limit inflammation in the central nervous system - a finding that could have important implications in the treatment of brain disorders such as multiple sclerosis. The research, led by Barrow's Fu-Dong Shi, MD, PhD, was published in the August 2010 issue of The Journal of Experimental Medicine, and simultaneously highlighted in Nature.

22 Oct 2010

ISCTM to develop solutions for CNS clinical trial methodology

The International Society for CNS Clinical Trials and Methodology (ISCTM) met recently to develop solutions to challenges facing CNS clinical trial methodology.

21 Oct 2010

Joint stem cell study to investigate multiple sclerosis

A $2.2 million project by Victorian and Californian researchers will assess whether stem cell therapies can be used to combat diseases such as Multiple Sclerosis and Type-1 diabetes, and help organ transplant recipients. Speaking at AusBiotech 2010 in Melbourne today, Innovation Minister Gavin Jennings said the Brumby Labor Government had contributed $575,505 to the project, the fifth to be funded through the $28 million Victoria–California Stem Cell Alliance which was established in 2008 under the Biotechnology Strategic Development Plan.

21 Oct 2010

Arena reports results of APD916 Phase 1 clinical trial for narcolepsy with cataplexy

Arena Pharmaceuticals, Inc. announced today results from a Phase 1 clinical trial of APD916, a novel drug candidate discovered by Arena that targets the histamine H3 receptor for the treatment of narcolepsy with cataplexy.

20 Oct 2010

Envoy expands drug discovery collaboration with The Scripps Research Institute

Envoy Therapeutics, Inc., a recently-formed drug discovery company, today announced that it has expanded its research collaboration with The Scripps Research Institute aimed at identifying new drugs for neurological and psychiatric diseases.

20 Oct 2010

Pfizer enters partnership with Teuto to develop, commercialize generic medicines

Pfizer Inc. announced today that it is entering into a partnership with Laboratorio Teuto Brasileiro S.A., a leading company in the Brazilian generics industry, to develop and commercialize generic medicines.

20 Oct 2010

Study finds massive blood transfusion associated with severe complications

A study presented at this year's American Society of Anesthesiologists Annual Meeting indicates that massive blood transfusion is associated with a significant increase in perioperative risk for mortality, cardiopulmonary complications, and wound-related and infectious complications in the long term.

20 Oct 2010

Rexahn announces publication of 3-aryl-1-isoquinolinamines preclinical data

Rexahn Pharmaceuticals, Inc. a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced the publication of new preclinical data on the development of 3-aryl-1-isoquinolinamines in the European Journal & Medicinal Chemistry.

19 Oct 2010

Pseudobulbar affect impacts majority of stroke survivors, but few have any understanding of condition

A survey released today by National Stroke Association shows that 53 percent of stroke survivor respondents suffer from symptoms of another neurologic condition called pseudobulbar affect (PBA), a condition thought to be caused by structural damage in the brain due to injury or disease. PBA causes involuntary and unpredictable outbursts of laughing or crying, often in socially inappropriate situations. Even though a significant proportion of stroke survivors suffer from PBA, fewer than one in five are familiar with the condition.

19 Oct 2010

STOP-BANG questionnaire on sleep apnea syndrome helps identify patients' risk for surgical complication

A research team from the Jefferson Sleep Disorders Center at Thomas Jefferson University Hospital has utilized a simple, eight-item pre-operative questionnaire about obstructive sleep apnea syndrome that could help identify patients at risk for complications following surgery, according to a report in the October issue of Archives of Otolaryngology-Head & Neck Surgery, one of the JAMA/Archives journals. Individuals prone to the obstructive sleep apnea syndrome as determined by the questionnaire appear to have an increased risk of heart, lung and other complications following elective surgery.

19 Oct 2010

Somaxon announces nonreceipt of Paragraph IV certification for generic Silenor ANDA

Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that the website of the U.S. Food and Drug Administration (FDA) indicates that an Abbreviated New Drug Application (ANDA) for a generic version of Silenor® (doxepin) 3 mg and 6 mg was submitted on September 16, 2010.

19 Oct 2010

Nektar presents data of NKTR-181 mu-opioid analgesic candidate at Pain 2010 Symposium

Nektar Therapeutics presented promising data today from preclinical studies of NKTR-181, a next-generation mu-opioid analgesic candidate with a novel molecular design. NKTR-181 is being developed to effectively treat pain while addressing the abuse liability and serious side effects associated with traditional opioid therapies.

18 Oct 2010

Central Nervous System News and Research

DiaGenic third quarter income increases from NOK -9.3 million to NOK -9.6 million

Scientists identify potential new treatment for Nipah and Hendra viruses

StemCells initiates HuCNS-SC second clinical trial for Batten disease in children

AACN joins call for system-wide programs for medication reconciliation

MedAvante's centralized ratings to be used in Rexahn's Serdaxin Phase 2a study in MDD patients

Salk discovers potential new target for MS

UCI scientists receive CIRM grants to improve stem cell treatments

Arena's NDA receives Complete Response Letter for lorcaserin

Scientists discover new cell that may limit inflammation in CNS

ISCTM to develop solutions for CNS clinical trial methodology

Joint stem cell study to investigate multiple sclerosis

Arena reports results of APD916 Phase 1 clinical trial for narcolepsy with cataplexy

Envoy expands drug discovery collaboration with The Scripps Research Institute

Pfizer enters partnership with Teuto to develop, commercialize generic medicines

Study finds massive blood transfusion associated with severe complications

Rexahn announces publication of 3-aryl-1-isoquinolinamines preclinical data

Pseudobulbar affect impacts majority of stroke survivors, but few have any understanding of condition

STOP-BANG questionnaire on sleep apnea syndrome helps identify patients' risk for surgical complication

Somaxon announces nonreceipt of Paragraph IV certification for generic Silenor ANDA

Nektar presents data of NKTR-181 mu-opioid analgesic candidate at Pain 2010 Symposium

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News